NEW YORK (TheStreet) -- Shares of Express Scripts (ESRX) were up in late afternoon trading on Monday as the pharmacy benefit management company prepares to report 2016 third quarter earnings after Tuesday's closing bell.
Analysts surveyed by FactSet are looking for the St. Louis-based company to post adjusted earnings of $1.73 per share on revenue of $25.51 billion.
In the year-ago period, Express Scripts reported adjusted earnings of $1.45 per share on revenue of $25.22 billion.
Credit Suisse said recently that despite calls to increase transparency in drug pricing, "we do not view the pharmacy benefit management model as at risk."
If customers adopt Express Scripts' new Care Value programs like hepatitis, cholesterol, anti-inflammatories and oncology, Express Scripts should see "profitable growth" in upcoming years, the firm said.
Credit Suisse has an "outperform" and $85 price target on Express Scripts shares.
Separately, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
TheStreet Ratings with a ratings score of B-.
The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, notable return on equity and compelling growth in net income. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.
You can view the full analysis from the report here: ESRX